The firm acquired intellectual property from Mammoth Biosciences that will reduce the speed and cost of its in-development point-of-care solution.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.